XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements
3 Months Ended
Mar. 31, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
Financial Instruments Measured at Fair Value on a Recurring Basis
The following tables set forth the Company’s financial instruments that were measured at fair value on a recurring basis as of the dates indicated by level within the fair value hierarchy (in thousands):
March 31, 2022
Level 1Level 2Level 3Total
Unrestricted Balances(1)
Money market funds$10,824 $— $— $10,824 
Certificates of deposit— 480,128 — 480,128 
Commercial paper— 1,194,329 — 1,194,329 
Corporate bonds— 165,082 — 165,082 
U.S. government securities— 3,095 — 3,095 
Marketable equity securities9,830 — — 9,830 
Total unrestricted cash equivalents and short-term investments20,654 1,842,634 — 1,863,288 
Restricted Balances(2)
Money market funds11,868 — — 11,868 
Certificates of deposit— 281,080 — 281,080 
Commercial paper— 485,042 — 485,042 
Corporate bonds— 65,742 — 65,742 
U.S. government securities— 46,098 — 46,098 
Total restricted cash equivalents and investments11,868 877,962 — 889,830 
Total unrestricted and restricted cash equivalents and investments$32,522 $2,720,596 $— $2,753,118 
_______________
(1)$48.1 million of cash, $115.1 million of money market deposit accounts and $210.0 million of term deposits are not subject to recurring fair value measurement and therefore excluded from this table. However, these balances are included within the $2.2 billion of cash and cash equivalents and short-term investments on the condensed consolidated balance sheets.
(2)$53.2 million of restricted cash and $5.0 million of a restricted term deposit are not subject to recurring fair value measurement and therefore excluded from this table. However, these balances are included within the $948.1 million of restricted cash and cash equivalents and restricted short-term investments on the condensed consolidated balance sheets.
December 31, 2021
Level 1Level 2Level 3Total
Unrestricted Balances(1)
Money market funds$22,250 $— $— $22,250 
Certificates of deposit$— $505,438 $— $505,438 
Commercial paper— 806,388 — 806,388 
Corporate bonds— 99,705 — 99,705 
Total unrestricted cash equivalents and short-term investments22,250 1,411,531 — 1,433,781 
Restricted Balances(2)
Money market funds20,161 — — 20,161 
Certificates of deposit— 421,144 — 421,144 
Commercial paper— 523,489 — 523,489 
Corporate bonds— 63,458 — 63,458 
U.S. government securities— 31,717 — 31,717 
Total restricted cash equivalents and investments20,161 1,039,808 — 1,059,969 
Total unrestricted and restricted cash equivalents and investments$42,411 $2,451,339 $— $2,493,750 
_______________
(1)$104.8 million of cash, $330.3 million of money market deposit accounts and $385.0 million of term deposits are not subject to recurring fair value measurement and therefore excluded from this table. However, these balances are included within the $2.3 billion of cash and cash equivalents and short-term investments on the condensed consolidated balance sheets.
(2)$53.7 million of restricted cash and $5.0 million of a restricted term deposit are not subject to recurring fair value measurement and therefore excluded from this table. However, these balances are included within the $1.1 billion of restricted cash and cash equivalents and restricted short-term investments on the condensed consolidated balance sheets.
The fair value of the Company’s Level 1 financial instruments is based on quoted market prices for identical instruments. The fair value of the Company’s Level 2 fixed income securities is obtained from an independent pricing service, which may use quoted market prices for identical or comparable instruments or model driven valuations using observable market data or inputs corroborated by observable market data. Level 3 instrument valuations are valued based on unobservable inputs and other estimation techniques due to the absence of quoted market prices, inherent lack of liquidity and the long-term nature of such financial instruments.
During the three months ended March 31, 2022, the Company did not make any transfers between the levels of the fair value hierarchy.
Financial Instruments Measured at Fair Value on a Non-Recurring Basis
Our non-marketable equity securities are investments in privately held companies without readily determinable fair values and the carrying value of our non-marketable equity securities are remeasured to fair value based on price changes from observable transactions of identical or similar securities of the same issuer (referred to as the measurement alternative) or for impairment. Any changes in carrying value are recorded within other income (expense), net in the condensed consolidated statements of operations.
In June 2021, the Company received an investment in a non-marketable equity security in a privately held company without a readily determinable market value as part of licensing and data access agreements. The investment had a carrying value of $64.0 million and is categorized as Level 3. The Company does not have the ability to exercise significant influence over this privately-held company and has elected to measure this investment as a non-marketable equity security and classified it in other investments on the condensed consolidated balance sheet. As of March 31, 2022, there were no remeasurement adjustments related to this non-marketable equity security.
In February 2022, the issuer of the Company's $10.0 million investment in non-marketable equity securities in a privately held company was acquired by a publicly-traded company. As a result of the acquisition in exchange for the securities in the privately-held entity, the Company received common stock of a publicly-traded entity with a value of $8.4 million, which shares are classified as marketable equity securities and measured at fair value on a recurring basis, with the remainder to be received in cash. The shares are categorized as Level 1 and changes in fair value are recorded within other income (expense), net in the condensed consolidated statements of operations.
At March 31, 2022, there were $70.2 million of financial instruments measured at fair value on a non-recurring basis within other investments on the condensed consolidated balance sheets.